The role of modulation of somatostatin analogues (SSAs) in association to peptide receptor radionuclide therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) entero-pancreatic neuroendocrine tumours (EP-NETs) [PDF]
, 2018 Natalie Prinzi +14 more
openalex +1 more source
Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? [PDF]
, 2018 Purpose: Gallium-68 is a metallic positron emitter with a half-life of 68min that is ideal for the in vivo use of small molecules, such as [68Ga-DOTA,Tyr3]octreotide, in the diagnostic imaging of somatostatin receptor-positive tumours.
Antunes, P. +6 more
core
A One-Year Review of the Radiation Safety Procedures and Protocols for Peptide Receptor Radionuclide Therapy (PRRT) Using Lutetium Lu 177 Dotatate [PDF]
, 2019 Will Snyder +5 more
openalex +1 more source
Correction to: Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis [PDF]
, 2017 Sue Ping Thang +6 more
openalex +1 more source
Italian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) practical guide for peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-Oxodotreotide in gastroenteropancreatic neuroendocrine tumors (GEP-NET) [PDF]
Riccardo Laudicella +11 more
openalex +1 more source
Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model [PDF]
, 2014 Sander Bison +6 more
openalex +1 more source
1163P Prognostic value of systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT) [PDF]
E. Terán Brage +16 more
openalex +1 more source